DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 118 filers reported holding DYNE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 4.08 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,140,086 | -20.4% | 1,912,956 | -0.0% | 0.01% | -10.0% |
| Q2 2023 | $21,526,639 | -1.3% | 1,913,479 | +1.1% | 0.01% | -9.1% |
| Q1 2023 | $21,799,976 | +5.8% | 1,892,359 | +6.4% | 0.01% | 0.0% |
| Q4 2022 | $20,610,508 | -9.0% | 1,778,301 | -0.3% | 0.01% | -8.3% |
| Q3 2022 | $22,643,000 | +88.7% | 1,782,871 | +2.1% | 0.01% | +100.0% |
| Q2 2022 | $11,999,000 | +5.7% | 1,746,481 | +48.3% | 0.01% | +20.0% |
| Q1 2022 | $11,355,000 | -19.9% | 1,177,948 | -1.2% | 0.01% | 0.0% |
| Q4 2021 | $14,178,000 | -22.2% | 1,192,398 | +6.3% | 0.01% | -28.6% |
| Q3 2021 | $18,215,000 | -16.4% | 1,121,613 | +8.3% | 0.01% | -12.5% |
| Q2 2021 | $21,796,000 | +50.7% | 1,035,947 | +11.2% | 0.01% | +33.3% |
| Q1 2021 | $14,462,000 | -54.2% | 931,205 | -38.0% | 0.01% | -53.8% |
| Q4 2020 | $31,546,000 | -10.6% | 1,502,205 | -14.0% | 0.01% | -23.5% |
| Q3 2020 | $35,283,000 | – | 1,747,557 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,220,034 | $25,730,194 | 34.58% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $57,385,602 | 24.01% |
| Atlas Venture Life Science Advisors, LLC | 9,869,483 | $114,387,308 | 13.78% |
| Logos Global Management LP | 2,150,000 | $24,918,500 | 2.92% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 641,068 | $7,417,157 | 2.29% |
| Deep Track Capital, LP | 2,684,200 | $31,109,878 | 1.31% |
| EcoR1 Capital, LLC | 2,322,384 | $26,916,431 | 0.82% |
| Vivo Capital, LLC | 577,642 | $6,695 | 0.77% |
| HighVista Strategies LLC | 102,431 | $1,187,175 | 0.70% |
| Monashee Investment Management LLC | 123,719 | $1,433,903 | 0.62% |